Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis

2021 ◽  
Author(s):  
R.M. Glicksman ◽  
A.U. Kishan ◽  
A.J. Katz ◽  
C.A. Mantz ◽  
S.P. Collins ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Response Rate ◽  
Specific Antigen ◽  
Intermediate Risk ◽  
Ablative Therapies ◽  
Risk Prostate Cancer

97: Four-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated with Ablative Therapies: The Sprat Analysis

2021 ◽  
Vol 163 ◽  
pp. S43
Author(s):  
Rachel Glicksman ◽  
Amar U. Kishan ◽  
Alan J. Katz ◽  
Constantine A. Mantz ◽  
Sean P. Collins ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Response Rate ◽  
Intermediate Risk ◽  
Ablative Therapies ◽  
Risk Prostate Cancer ◽  
Psa Response

The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer

2012 ◽  
Vol 36 (2) ◽  
pp. e137-e141 ◽  
Author(s):  
Guila Delouya ◽  
Gabriel Kaufman ◽  
Marie-Pierre Sylvestre ◽  
Thu-Van Nguyen ◽  
Jean-Paul Bahary ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
External Beam Radiotherapy ◽  
Specific Antigen ◽  
External Beam ◽  
Intermediate Risk ◽  
Risk Prostate Cancer

Men Older Than 70 Years Have Higher Risk Prostate Cancer and Poorer Survival in the Early and Late Prostate Specific Antigen Eras

2009 ◽  
Vol 182 (5) ◽  
pp. 2242-2249 ◽  
Author(s):  
Leon Sun ◽  
Arthur A. Caire ◽  
Cary N. Robertson ◽  
Daniel J. George ◽  
Thomas J. Polascik ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document